|EntreChem participates in the ERA-IB project «NeBrasCa - Next Generation Immunosuppressants: Brasilicardin synthesized by Nocardia spp»
May 7th, 2015 - Oviedo (Spain)
||EntreChem and three Universities from three European countries to cooperate in the project.
||The European Commission has awarded €1 million to the ERA-IB project "NeBrasCa - Next Generation Immunosuppressants: Brasilicardin synthesized by Nocardia spp." The project belongs to the European Research Agency - Industrial Biotechnology program (ERA-IB), and it aims to develop new brasilicardin analogs as new immunosuppressant drugs.
Professor Dr. Harald Groß, from the Department of Pharmaceutical Biology, of the Pharmaceutical Institute of Tübingen University (Germany), coordinates the project. EntreChem is the only company participating in the consortium, together with the Universities of Tübingen, Oviedo and Wroclaw.
Brasilicardin is a terpenoid secondary metabolite which is known to have an immunosuppressive activity and is produced by the soil bacterium Nocardia terpenica. It targets the amino acid transport system L and exhibits therefore a completely different mode of action than the established drugs. Brasilicardin analogs would represent a valuable drug option that can expand and complement todays immunosuppressant therapy.